This Article Full Text Full Text (PDF) Correction (v111,p377) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huynh, T. Articles by Solymoss, S. Search for Related Content PubMed PubMed Citation Articles by Huynh, T. Articles by Solymoss, S. Related Collections Secondary prevention Coumarins Platelet function inhibitors CV surgery: coronary artery disease

(Circulation. 2001;103:3069.)
© 2001 American Heart Association, Inc.

Clinical Investigation and Reports

Aspirin, Warfarin, or the Combination for Secondary Prevention of Coronary Events in Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Surgery

Thao Huynh, MD; Pierre Théroux, MD; Peter Bogaty, MD; James Nasmith, MD; Susan Solymoss, MD

From the Montreal General Hospital (T.H., S.S.), the Montreal Heart Institute (P.T.), and Sacré-Coeur Hospital (J.N.), Montreal, Quebec, and the Quebec Heart Institute (P.B.), Quebec, Quebec, Canada.

Background—Patients with a non–ST-elevation acute coronary syndrome and prior CABG are at high risk of a recurrent ischemic event despite aspirin therapy. This trial investigated the potential benefit of secondary prevention with warfarin.

Methods and Results—In a double-blind randomized trial, 135 patients with unstable angina or non–ST-segment elevation myocardial infarction, with prior CABG, and who were poor candidates for a revascularization procedure received therapy with aspirin and placebo+warfarin, warfarin and placebo+aspirin, or aspirin and warfarin for 12 months. Warfarin was titrated to an international normalized ratio of 2.0 to 2.5. The primary end point (death or myocardial infarction or unstable angina requiring hospitalization 1 year after randomization) occurred in 14.6% of the patients in the warfarin-alone group, in 11.5% of patients in the aspirin-alone group, and in 11.3% of patients randomized to the combination therapy (P=0.76). Subgroup analyses by risk features provided no indications that warfarin alone or in combination with aspirin could be of benefit over aspirin alone. Bleeding was more frequent in the 2 groups of patients administered warfarin.

Conclusions—Moderate-intensity oral anticoagulation alone or combined with low-dose aspirin does not appear to be superior to low-dose aspirin in the prevention of recurrent ischemic events in patients with non–ST-elevation acute coronary syndromes and previous CABG.

Key Words: warfarin sodium • anticoagulants • aspirin • coronary disease

This article has been cited by other articles:

				F. Dentali, J. D. Douketis, W. Lim, and M. Crowther Combined Aspirin-Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: A Meta-analysis of Randomized Trials Arch Intern Med, January 22, 2007; 167(2): 117 - 124. [Abstract] [Full Text] [PDF]

				F. Andreotti, L. Testa, G. G.L. Biondi-Zoccai, and F. Crea Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients Eur. Heart J., March 1, 2006; 27(5): 519 - 526. [Abstract] [Full Text] [PDF]

				M. B. Rothberg, C. Celestin, L. D. Fiore, E. Lawler, and J. R. Cook Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit Ann Intern Med, August 16, 2005; 143(4): 241 - 250. [Abstract] [Full Text] [PDF]

				R. G. Hart, S. B. Tonarelli, and L. A. Pearce Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas Stroke, July 1, 2005; 36(7): 1588 - 1593. [Abstract] [Full Text] [PDF]

				J. Herlitz, J. Holm, M. Peterson, B. W Karlson, M. Haglid Evander, L. Erhardt, and for the LoWASA study group Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction: the LoWASA Study Eur. Heart J., February 1, 2004; 25(3): 232 - 239. [Abstract] [Full Text] [PDF]

				M.J. Zibaeenezhad, A. Mowla, and M.H. Sorbi Warfarin and Aspirin Versus Aspirin Alone in Patients with Acute Myocardial Infarction: A Pilot Study Angiology, January 1, 2004; 55(1): 17 - 20. [Abstract] [PDF]

				A. S Jeddy and B. L Gleason Aspirin and Warfarin Versus Aspirin Monotherapy After Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1502 - 1505. [Abstract] [Full Text] [PDF]

				J. M. Foody, F. D. Ferdinand, D. Galusha, S. S. Rathore, F. A. Masoudi, E. P. Havranek, D. Nilasena, M. J. Radford, and H. M. Krumholz Patterns of Secondary Prevention in Older Patients Undergoing Coronary Artery Bypass Grafting During Hospitalization for Acute Myocardial Infarction Circulation, September 9, 2003; 108(90101): II-24 - 28. [Abstract] [Full Text] [PDF]

				S. S. Anand and S. Yusuf Oral anticoagulants in patients with coronary artery disease J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 62S - 69S. [Abstract] [Full Text] [PDF]

				J.P. Mohr, J.L.P. Thompson, R.M. Lazar, B. Levin, R.L. Sacco, K.L. Furie, J.P. Kistler, G.W. Albers, L.C. Pettigrew, H.P. Adams Jr., et al. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke N. Engl. J. Med., November 15, 2001; 345(20): 1444 - 1451. [Abstract] [Full Text] [PDF]